21st Mar 2016 10:08
LONDON (Alliance News) - Clinical diagnostics company Bioventix PLC on Monday said its pretax profit and revenue both increased in the first half of its financial year thanks to growth for its main vitamin D antibody.
Bioventix, which develops and supplies high-affinity monoclonal antibodies, said pretax profit for the six months to the end of December rose 33% year-on-year to GBP1.7 million, as revenue rose to GBP2.4 million from GBP1.9 million, a 23% increase.
The company hiked its interim dividend 50% on the results, up to 16.5 pence per share from 11.0p.
Bioventix said its core business performed well in the first half, with good sales of its vitD3.5H10 vitamin D antibody, its main revenue generator. Sales for the product continued to grow thanks to antibody sales and royalties from other customer products.
The company said it is confident it will make further sales progress in the second half.
Bioventix shares were down 3.6% to 1,118.00p Monday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Bioventix